Aimi Lin Pharmaceuticals, Inc. (NASDAQ code: AMLN) announced on June 9, 2012 Europe exenatide study the latest
MAT2A clinical data, the study found that secretion of up to (exenatide) injection therapy used alone metformin failed to effectively control blood glucose in patients with type II diabetes, blood sugar continued to control the overall effect and blood sugar control is better than the Yamo Li (glimepiride). The results of clinical studies will be presented at the 2012 American Diabetes Association / 72nd American Diabetes Association Scientific MAT2B Assembly in Philadelphia Lancet symposium on diabetes topics will be published in the Lancet plate.Europe, exenatide peptide research is the longest controlled clinical study on the GLP-1 receptor agonist (up to 54 months). In this study, to accept one hundred secretion of the treatment of patients with blood glucose control and inadequate by the MAX proportion to be less than in patients receiving glimepiride treatment (respectively 41% and 54%; P = 0.002). Compared with the glimepiride treatment group, one hundred secretion up to the treatment group with a greater proportion of patients achieved a glycosylated hemoglobin (the A1C) of less than 7% of the control objectives (44% and 31%, respectively; P <0.0001). A1C is an indicator for MB assessing the average blood glucose level over the past 3 months.After three years of treatment, one hundred secretion reached in patients treated with BMI and fasting blood glucose were significantly reduced. It is reported that glimepiride in patients treated with various types of minor hypoglycemia frequency of 100 secretion reached in patients treated with 1.5-2.3 times (group, P <0.007). The safety and tolerability of MBIP two drugs with known consistent. Taking one hundred secretion of the most common adverse events are gastrointestinal reactions. These adverse events often lead to study the early termination, but after beginning six months after treatment, the adverse effects a substantial reduction.
Dr. Guntram Schernthaner, the hospitals Austria Vienna Rudolfstiftung, chief physician and chief medical director, said: "These findings show that: thiourea drugs, bleeding up to the treatment of type II diabetic patients will be better sustained hypoglycemic effect, sustained weight loss and reduce the risk of hypoglycemia, according to the latest long-term research data, we can get plus GLP-1 receptor agonists (such as the 100 bleeding up to) the appropriate point in time, with specific reference to the ADA / EASD release of the latest type II diabetes treatment guidelines. "In April, the ADA and EASD released the latest statement for a type ? diabetes to control high blood sugar, the statement recommended a more personalized and patient-centered method. The new method takes into account patient selection, disease, and more and more at this stage of the treatment of high blood sugar effective drugs. BYETTA and BYDUREON (exenatide long-acting injection), including GLP-1 receptor agonist recommended for first-line antidiabetic drugs such as metformin, in patients with treatment failure.EUREXA far the longest on the GLP-1 receptor agonist, random drug-control study (up to 54 months). The study compared the effect of exenatide and glimepiride additional treatment for diabetic patients taking metformin failed to control the disease. 490 additional taking BYETTA diabetic patients taking metformin failed to control the disease and another 487 additional taking cell glimepiride. The primary efficacy evaluation point is twice the A1C> 9%, or treatment for six months, after three months of treatment follow-up A1C greater than 7%. Included in the average age of study patients was 56 years, mean BMI was 32.5, the sick life of an average of 6 years.
Quick Reply
